Nerai Bioscience has raised $181K from Venture Kick, the Swiss early-stage investor known for backing university spinouts.
The company is building a new generation of CRISPR enzymes designed to reach genomic targets that current editing tools can't touch. Its MORPHEME platform pairs AI with high-throughput protein engineering and directed evolution to design bespoke editors, with an eye on rare and complex genetic diseases.

















